Print
Email
Print Edition Stories
Regenerative medicine firms make business of creating skin
MHT's Julie Donnelly: Biotechs lag in social media use
Cambridge biopharmaceutical firm Cerulean Pharma Inc. has raised $1.5 million in a securities offering, according to a filing with the U.S. Securities and Exchange Commission.
The regulatory filing indicates that Cerulean’s offering included debt and warrants.
Cerulean is focused on developing novel nanotechnology-based therapeutics in the areas of oncology, cardiovascular, autoimmune and inflammatory diseases.
In 2009, Cerulean closed a $10 million Series B-1 funding round, backed by return investors Polaris Venture Partners of Waltham, Bessemer Venture Partners of Wellesley, and Venrock and Lux Capital, both of New York.
The company overhauled its image in recent years, changing its name from Tempo Pharmaceuticals in 2008 and, in 2009, appointing Oliver Fetzer as president and CEO ; John Ryan as senior vice president, chief medical officer ; and Karen Roberts as senior vice president, finance and administration.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
